Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized double-blind placebo-controlled trial of BMS-986165 in moderate-to-severe plaque psoriasis
CTR20191405Phase 3Completed
- Sponsor
- Bristol Myers Squibb
- Start
- Sep 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of deucravacitinib in plaque psoriasis, sponsored by Bristol Myers Squibb. Started Sep 2019; status: completed.
02
Drugs
deucravacitinib
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on CTR20191405.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20191405.